NSG and Acclivis sign deal to develop AI genomics workflow

New Silkroutes Group Limited (NSG), a Singaporean investment holding company, has signed a Memorandum of Understanding (MOU) with cloud provider Acclivis Technologies and Solutions to develop a new solution for an artificial intelligence (AI) platform that provides genomic-driven healthcare. 

The non-binding MOU covers the development of a private AI cloud facility and secure network connection that will pull genomics data from cloud data storage to produce clinical reports for medical practitioners and clinicians. The system will have machine learning capability, so that the clinical reports it produces will become more intelligent over time, increasing usage. 

Through its subsidiary Healthsciences International Pte Ltd, NSG owns a number of primary care and dental facilities in Singapore and Vietnam, as well as pharmacy management systems in Singapore and China. The company will own the intellectual property rights for the new workflow and the user interface of the platform. 

Dr VicPearly Wong, NSG’s Chief Executive Officer said that the solution - called GEIATM - is a complete, seamless, hybrid cloud-based solution. “We have been working hard to enhance our AI capabilities to transform ourselves into a tech-enabled healthcare group that will provide patients with the best diagnosis and treatment. We look forward to launching GEIATM , our very own AI solution soon" he said. 

Mr Marcus Cheng, Chief Executive Officer of Acclivis, added: “Acclivis has a track record of building and managing private cloud facilities and developing AI technology platforms that define, structure and automate workflows for the public, commercial and healthcare sectors. We are delighted to partner with NSG to positively shape the future of genomics healthcare.”

NSG is currently focused on becoming a leading health tech player in the Asia Pacific region. Earlier this year the firm entered into a collaboration with Huawei to develop its AI-driven platform, to build predictive models for cancer along with other conditions. 

“NSG will continue to build relationships with leading tech players who can provide us with a full range of capabilities in data-driven diagnostics” Dr Wong added.